বাংলায় পড়ুন
On 15th December 2017, Eastern India witnessed one of the most inimitable events in the history of medical science with due aid of Suraksha Diagnostics Pvt. Limited. Along with the presence of prominent medics Dr. Tridip Chatterjee (scientist molecular biology), Dr. Diptendra Kumar Sarkar (consultant surgeon, breast surgeon and surgical oncologist), Dr. Disha Banerjee (scientific officer, Thermo Fisher), Dr Anupama Gaur (clinical sequencing diagnostics leader South Asia for Thermo Fisher) Suraksha Diagnostics Pvt. Limited announced the introduction of the Next Generation Sequencing technology to be accessible widely in Eastern India for the very first time at a very evenhanded price.
Next Generation Sequencing technology launching event ostentatiously took place at “The grand Oberoi”, Kolkata in association with Candid Communication. The graceful presence of the distinguished doctors had altogether enriched the concept of the Next Generation Sequencing technology among the populaces. Health has become a staple of concern in the contemporaneous scenario and depending on the exclusive plea of the mass they have been into the research on this for pretty long. Thereby, they felt glad to be a part of the entire session for the good of the common people.
Question arises, what exactly is Next Generation Sequencing technology. NGS is actually an approach for DNA sequencing using the notion of colossally parallel processing. It is sure to propose accurate and much cost effective diagnosis and prognosis. It would definitely enhance the targeted treatment system and monitor the solutions in a much better approach. Next Generation Sequencing technology has the doles of high sensitivity, accuracy and speed in the process of treatment, which is of absolute necessity in the study and treatment segment of oncology.
“We worked hard on this and finally we are happy to present the ultimate solution to the people. We are sure that people will achieve the best treatments through Next Generation Sequencing technology. Moreover this is pocket friendly and fits the budget of people from all background. This much expense is worth to get the desired results” says Dr. Tridip Chatterjee (scientist molecular biology)
“We are focused on the Breast cancer (BRCA 1 and 2) screening and comprehensive panel, Non invasive prenatal screening (NIPS) and Pre implantation Genetic Screening (PGS) along with the concept of Next Generation Sequencing technology. We are concentrating on this because this will become an indispensable tool for personalized medicine, which is responsible for the transformation of the diagnostic methodologies of clinical molecular genetics. It empowers deep sequencing for mutation detection” says Dr. Somnath Chatterjee, Director, Suraksha Diagnostics Pvt. Limited.
